With alleles such as HLA-A*68:01 emerging as disproportionately high in their immunoediting score, we will be interested to see whether contributions of HLA alleles to early immunoediting will translate to improved abilities to induce T cell responses against tumor neoantigens in patients, and whether such alleles are associated with improved outcomes in patients treated with modern immunotherapies. Here, HLA-A is linked to neoplasm.